US 12,083,082 B2
Methods for treating neurodegenerative disorders
John Hey, Framingham, MA (US); Petr Kocis, Framingham, MA (US); Martin Tolar, Framingham, MA (US); and Neil William Flanzraich, Coral Gables, FL (US)
Assigned to Alzheon, Inc., Framingham, MA (US)
Appl. No. 17/264,477
Filed by Alzheon, Inc., Framingham, MA (US)
PCT Filed Jul. 30, 2019, PCT No. PCT/US2019/044023
§ 371(c)(1), (2) Date Jan. 29, 2021,
PCT Pub. No. WO2020/028290, PCT Pub. Date Feb. 6, 2020.
Claims priority of provisional application 62/713,061, filed on Aug. 1, 2018.
Prior Publication US 2021/0315847 A1, Oct. 14, 2021
Int. Cl. A61K 31/19 (2006.01); A61K 31/185 (2006.01); A61P 25/28 (2006.01)
CPC A61K 31/19 (2013.01) [A61K 31/185 (2013.01); A61P 25/28 (2018.01)] 9 Claims
OG exemplary drawing
 
1. A method of treating a subject suffering from Alzheimer's disease comprising the step of administering to the subject an effective amount of a compound having the Formula I:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, wherein R is —COOH.